Annovis Bio Appoints Mark Guerin as CFO to Advance Neurodegenerative Disease Drug Development

Annovis Bio has appointed Mark Guerin as Chief Financial Officer to support the company's advancement of buntanetap through late-stage clinical trials for neurodegenerative diseases. Guerin brings extensive financial leadership experience from his previous role as CFO of Onconova Therapeutics, now Traws Pharma, where he managed multiple financings and oversaw the merger that formed the new entity. His background includes senior finance positions at Cardiokine, Barrier Therapeutics, and Coopers & Lybrand, providing him with the expertise needed to navigate the complex financial landscape of late-stage drug development.

The appointment comes at a critical juncture for Annovis Bio as its lead drug candidate, buntanetap, progresses through registrational studies for Alzheimer's and Parkinson's disease. Guerin expressed enthusiasm about joining the company during this pivotal phase, stating his commitment to supporting Annovis in replicating buntanetap's early success in larger clinical trials. This strategic hire signals the company's preparation for the financial and operational demands of bringing a potential new therapy to market for patients suffering from these debilitating neurodegenerative conditions.

Annovis Bio's focus on developing therapies for neurodegenerative diseases positions the company in a high-need therapeutic area where effective treatments remain limited. The company maintains its corporate information at https://www.annovisbio.com and provides investor updates through its newsroom at https://ibn.fm/ANVS. Guerin's appointment represents a significant step in strengthening the company's financial leadership as it approaches potentially transformative clinical milestones. His experience in managing financial operations through mergers and multiple financing rounds will be invaluable as Annovis navigates the capital-intensive process of drug development and potential commercialization.

The neurodegenerative disease market represents a substantial unmet medical need, with Alzheimer's disease affecting approximately 6.7 million Americans aged 65 and older, according to Alzheimer's Association estimates. Parkinson's disease impacts nearly one million people in the United States, with about 90,000 new cases diagnosed annually. Successful development of buntanetap could address significant patient populations currently lacking disease-modifying treatments. Guerin's financial acumen will be crucial in managing the resources required for large-scale clinical trials and potential regulatory submissions.

BioMedWire, the specialized communications platform that distributed the announcement, provides sector-specific coverage of biotechnology and biomedical developments through its website at https://www.BioMedWire.com. The platform operates as part of the Dynamic Brand Portfolio at IBN, offering comprehensive distribution services including wire solutions, editorial syndication, and social media distribution. Guerin's appointment underscores Annovis Bio's commitment to building a strong leadership team capable of advancing buntanetap through the final stages of clinical development and potential regulatory approval processes.